Fig. 2From: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestationALT, AST, TBIL and HBV DNA levels at baseline and at delivery. Panel a was ALT, panel b was AST, panel c was TBIL, and panel d was HBV DNA.* means P < 0.05, compared with that before the treatment in the same drug groupBack to article page